

# Joint Programming Initiative on Antimicrobial Resistance



**Laura Marin**  
Manager JPIAMR

Swedish Research Council

# Why JPIAMR?

## Modern medicine depends on access to effective antibiotics:

### Antibiotics revolutionized medicine!


- The introduction of penicillin in the 1950's increased the chance of survival for pneumonia patients from 25% to 80%




The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart your computer, and then open the file again. If the red x still appears, you may have to delete the image and then insert it again.

#### Antibiotic Resistance threatens to return us to the pre-antibiotic era

- In Tanzania, Antibiotic Resistance has decreased the rate of survival from neonatal gram-negative infections from 70% to 20%



In the EU, **more than 25 000 patients** die from multidrug resistant bacteria annually (EMA/ECDC report)



Extra health-care costs and productivity losses of **at least 1,5 billion EURO per year**


# Why JPIAMR?

Few new drugs being developed


Excessive use of antibiotics



Increasing number of resistant strains



Great societal costs




AMR research in Europe is fragmented

AMR is a global problem:  
a societal challenge

# The AMR complexity.....

**.....leads to a problem which cannot be tackled by one scientific domain or even by research alone but that needs a collaborative approach**



# What is Joint Programming?

Joint Programming is a collaborative approach to research in which countries come together to define a common vision, a strategic research agenda and a management structure, in order to address the 'grand challenges' facing EU society.


It aims to pool national research efforts and to overcome the fragmentation of national research programmes.

# The JPIAMR – Aims


- To develop scientific proposals which will lead to sustainable use of antibiotics to treat infections diseases and to a decrease in the number of patients with resistant infections in Europe.
- To integrate relevant scientific fields across national borders and to create a common Strategic Research Agenda with a shared common vision where the best resources and capabilities are coordinated.
- To provide the forum and platform for initiating and coordinating joint actions and alignment activities jointly with Stakeholders beyond issuing joint calls.



# Governance Structure *(since 2012)*



# JPIAMR Participating countries (19)




Belgium      Canada      Czech Republic      Denmark      Finland



France      Germany      Greece      Israel      Italy



Netherlands      Norway      Poland      Romania      Spain



Sweden      Switzerland      Turkey      United Kingdom

← Estonia



# Membership: Members

- The nominated Management Board member has a governmental mandate
- All Members are represented in the Management Board (max. 2 representatives)
- They have voting rights
- Active contribution to the activities of JPIAMR is expected:
  - Attend regularly Management Board meetings
  - Be a member of at least 1 MB Working Group
  - Participate in some of the Joint Actions
  - Answer to the official JPIAMR surveys
- Contribution to JPIAMR operations:
  - Contribute in-kind for participation in meetings, workshops, WGs events and travel costs of member's representatives
  - Contribute in-kind with the organisation of some of the JPIAMR meetings or workshops

# The Strategic Research Agenda (SRA): uniting under one strategy



- To bring together all players in the field for a multi-dimensional approach
- To provide a platform for partners to collaborate in a tailor-made fashion on specific topics
- To harmonise joint actions and create greater impact
- To reduce research overlaps
- To create awareness and knowledge
- To stand a chance of actually finding a solution to the AMR problem




# The Strategic Research Agenda (SRA)

- First draft by the Scientific Advisory Board in collaboration with the Stakeholders Advisory Board
  - 2011-2013
- JPIAMR SRA Conference →
  - Geneva, May, 2013
- Brainstorming workshop at FEMS
  - August 2013
- Public and national consultation
  - September-October 2013
- Member State approval
  - December 2013
- Publication: January 2014
- Official launch
  - 3 April 2014



# SRA priority topics



## Therapeutics (A)

- Development of novel antibiotics and alternatives for antibiotics – from basic research to the market.

## Diagnostics (B)

- Design strategies to improve treatment and prevention of infections by developing new diagnostics.

## Surveillance (C)

- Standardisation and extension of surveillance systems to establish a global surveillance programme on antibiotic resistance and antibiotic use.

## Transmission (D)

- Transmission dynamics

## Environment (E)


- The role of the environment as a source for the selection for and spread.

## Interventions (F)

- Designing and testing interventions to prevent acquisition, transmission and infection caused by AMR.

# What exactly is the Strategic Research Agenda?

- The first step to drafting future research programmes
- A framework to begin joint actions
- A framework for creating an extensive trans-European work programme on AMR



# SRA launch conference

## *"Implementing a Global Research Agenda for AMR"*

Brussels April 3, 2014

Report:

[http://www.jpiamr.eu/wp-content/uploads/2014/06/  
OnlineBrochure12-06-2014.pdf](http://www.jpiamr.eu/wp-content/uploads/2014/06/OnlineBrochure12-06-2014.pdf)

### Speakers

- [Lena Furmark](#), Ministry of Health and Social Affairs, Sweden
- [Máire Geoghegan-Quinn](#), European Commissioner for Research, Innovation and Science
- [Carmen Pessoa](#), World Health Organisation
- [John Watson](#), Deputy Chief Medical Officer at the Department of Health, UK
- [Richard Bergström](#), Director, EPFIA
- [John Savill](#), Chief Executive of the Medical Research Council, UK
- [Dennis M. Dixon](#), Chief, Bacteriology and Mycology Branch, National Institute of Allergy and Infectious Diseases, NIH, USA
- [Nireesh Bhagwandin](#), Director, National Research Foundation of South Africa
- [Warwick Anderson](#), CEO, National Health & Medical Research Council, Australia
- [Marcelo Gala](#), Director, National Institute for Infectious Diseases, Argentina





**DRAFT Agenda 31-01-14**

**Joint Workshop**

**Antibiotics and their alternatives – fixing and feeding the pipeline**

**Date: 4 April 2014 Brussels**

**Objectives:**

- To present research results of recently completed FP7 projects that aimed to develop novel targets and drugs against Gram negative bacteria
- To present the development and discovery platforms that are being set up within IMI projects
- To present new collaborative research projects (with an SME focus) on the development of new drugs, vaccines and alternative methods
- To discuss the most efficient ways of ensuring exploitation of results in order to feed the pipeline.

- Report: [http://www.jpiaamr.eu/wp-content/uploads/2014/08/amr-workshop-report042014\\_en.pdf](http://www.jpiaamr.eu/wp-content/uploads/2014/08/amr-workshop-report042014_en.pdf)

*Now that the SRA is launched...*



# Implementation phase 2014-2015

## Mapping and Evaluation Activities

- National and international mapping exercises. Gap analysis - scale and scope of research activity. Framework of Evaluation.
- Analysis of output and bibliometrics for EU funded AMR research projects

## Internationalisation activities

- Jointly develop with the WHO an AMR Global Research Agenda
- Work towards partnership with countries outside Europe

## Alignment of research plans

- Work with member countries to align national research plans with the SRA

## Exploratory / Scoping research workshops

- Research infrastructures, diagnostics, therapeutics


## Calls

- First call “InnovaResistance” January, 2014
- Proof of concept call 2015
- Horizon2020 ERA-Net Cofund joint call 2016

# Mapping Research Investment


*Total number of projects and investment of public funds: Totals include all public funds in AMR research since 2007 (above 100keur), including national data from participating countries and the EC (FP 6, FP 7, DG-SANCO, ECDC, and ECs contribution to IMI). Total investments have been rounded to the nearest million euros.*

Aprox.  
1,500 projects funded  
Aprox.  
€100 million/year in funding



# Mapping Research Investment

*Total number of projects per country by priority topic: Totals include national data from participating countries since 2007 and do not include EC & IMI data. Some projects are classified under more than one priority topic.*



# Joint Calls

## First translational call -InnovaResistance-

- Title: Innovative approaches to address antibacterial resistance
- 13 participating countries
- Open: January 27 to March 14, 2014, for pre-proposals
- Consortia: Min 3 participating countries, max 6 partners
- Aim: *The primary aim of this first joint call of JPIAMR is to combine the resources, infrastructures, and research strengths of multiple countries in order to overcome antibiotic resistance.*

*Number of submitted proposals: 90 Invited to Second Stage: 40*

*Total requested funding (submitted): 104M €. Available 16M eur*

Financial Overview Submitted Proposals

PTJ submission platform




Partnering Tool

Call Documents

Guidelines for Applicants

Legal Notice



### Contact

If you have questions concerning the application process, please contact

**Dr. Henrike Knizia**

Phone: +49 (0) 24 61 61

h.knizia@fz-juelich.de

# Other activities in with Stakholders and international partners in progress

Link to other initiatives with common interests (e.g WHO)

Engagement plan with the industry:  
Joint Group EC-JPI-IMI – EPFIA

Joint Action with DG Sanco



European Federation of Pharmaceutical Industries and Associations



# Alignment action lines

1. Alignment with national strategies on AMR
2. Alignment with national funding
3. Alignment at institutional level
4. Aligning resources and technologies
5. Alignment with Industry
6. Aligning with national policies

# Thank you

More information at:

<http://www.jpiamr.eu/>